NCT04467138View on ClinicalTrials.gov

High Dose Intravenous Fish Oil Reduces Inflammation

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Lipid Metabolism Disorders
Interventions
DRUG

Omegaven

Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.

Trial Locations (1)

32-050

Stanley Dudrick's Memorial Hospital, Skawina

All Listed Sponsors
lead

Stanley Dudrick's Memorial Hospital

OTHER

NCT04467138 - High Dose Intravenous Fish Oil Reduces Inflammation | Biotech Hunter | Biotech Hunter